Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies
- 7 May 2020
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (9), 1917-1926
- https://doi.org/10.1182/bloodadvances.2019001079
Abstract
CD27, a costimulatory molecule on T cells, induces intracellular signals mediating cellular activation, proliferation, effector function, and cell survival on binding to its ligand, CD70. Varlilumab, a novel, first-in-class, agonist immunoglobulin G1 anti-CD27 antibody, mediates antitumor immunity and direct killing of CD27+ tumor cells in animal models. This first-in-human, dose-escalation, and expansion study evaluated varlilumab in patients with hematologic malignancies. Primary objectives were to assess safety and the maximum tolerated and optimal biologic doses of varlilumab. Secondary objectives were to evaluate pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity. In a 3 + 3 dose-escalation design, 30 patients with B-cell (n = 25) or T-cell (n = 5) malignancies received varlilumab (0.1, 0.3, 1, 3, or 10 mg/kg IV) as a single dose with a 28-day observation period, followed by weekly dosing (4 doses per cycle, up to 5 cycles, depending on tumor response). In an expansion cohort, 4 additional patients with Hodgkin lymphoma received varlilumab at 0.3 mg/kg every 3 weeks (4 doses per cycle, up to 5 cycles). No dose-limiting toxicities were observed. Treatment-related adverse events, generally grade 1 to 2, included fatigue, decreased appetite, anemia, diarrhea, and headache. Exposure was linear and dose-proportional across dose groups and resulted in increases in proinflammatory cytokines and soluble CD27. One patient with stage IV Hodgkin lymphoma experienced a complete response and remained in remission at >33 months with no further anticancer therapy. These data support further investigation of varlilumab for hematologic malignancies, particularly in combination approaches targeting nonredundant immune regulating pathways.This publication has 26 references indexed in Scilit:
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's LymphomaThe New England Journal of Medicine, 2015
- Agonist Anti-Human CD27 Monoclonal Antibody Induces T Cell Activation and Tumor Immunity in Human CD27–Transgenic MiceThe Journal of Immunology, 2013
- CD27 Signaling Increases the Frequency of Regulatory T Cells and Promotes Tumor GrowthCancer Research, 2012
- Development of a Human Monoclonal Antibody for Potential Therapy of CD27-Expressing Lymphoma and LeukemiaClinical Cancer Research, 2012
- Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412The New England Journal of Medicine, 2006
- CD27 Promotes Survival of Activated T Cells and Complements CD28 in Generation and Establishment of the Effector T Cell PoolThe Journal of Experimental Medicine, 2003
- CD148 and CD27 are Expressed in B Cell Lymphomas Derived from both Memory and Naïve B CellsLeukemia & Lymphoma, 2002
- CD27/CD70 interaction directly induces natural killer cell killing activityImmunology, 1996
- CD27-CD70 interactions regulate B-cell activation by T cells.Proceedings of the National Academy of Sciences of the United States of America, 1995
- CD27/CD70 interaction directly drives B cell IgG and IgM synthesisEuropean Journal of Immunology, 1995